

Supplemental Table 1: Overview of sampling procedures in the phase 3 trials

	Sampling Month															
Study	0	0.5	1	2	3	4	4.5	5	5.5	6	7	8	9	10	11	12
Phase 3																
	Double-Blind Treatment Period															
REGAIN																
Dosing	X		X	X	X											
ADA	X	X	X	X	X											
GMB (PK)		X	X	X	X											
CGRP (PD)	X	X	X	X	X											
	Double-Blind Treatment Period															
EVOLVE-1 and -2																
Dosing	X		X	X	X	X		X								
ADA	X	X	X	X	X					X						
GMB (PK)		X	X	X	X	X	X	X	X	X						
CGRP (PD)	X	X	X	X	X	X	X	X	X	X						
	Open-Label Treatment Period															
Study CGAJ																
Dosing	X		X	X	X	X		X		X	X	X	X	X	X	
ADA	X	X	X	X	X					X						X
GMB (PK)		X	X	X	X					X						X
CGRP (PD)	X	X	X	X	X					X						X

ADA = anti-drug antibodies; CGRP = calcitonin gene-related peptide; GMB = galcanezumab; PK = pharmacokinetic; PD = pharmacodynamic.